The pan-HDAC inhibitor ITF2357 is approved as a treatment for Duchenne muscular dystrophy [48,49] and showed high activity in our system, indicating it may also be effective against cachexia-induced skeletal muscle loss. Here, HDAC9 is linked to Duchenne muscular dystrophy.